- €3.84bn
- €4.67bn
- €1.20bn
Brief: Diasorin, Fy Adjusted EBITDA Eur 394 Mln
Italy - Factors to watch on March 14
Brief: Diasorin Shareholders Approve Enhanced Majority Voting System
Italy - Factors to watch on Feb. 28
Top of the Street: EssilorLuxottica, BPER, UBS, DiaSorin, Lifco and Indutrade
Europe Research Roundup: Adidas, L'Oreal, Next
RBC sees growth in IVD market, favours bioMérieux over Diasorin
Italy - Factors to watch on November 6
Refile: UPDATE 1-Diagnostics group DiaSorin's nine-month adjusted core profit up 6%
Diagnostics group DiaSorin's nine-month adjusted core profit up 6%
Brief: Diasorin Q3 Adj. EBITDA At EUR 94 Mln
Italy - Factors to watch on November 5
Europe Research Roundup: Ashmore, Biomerieux, Diasorin
Europe Research Roundup: Adyen NV, Beazley, Nel ASA
DiaSorin raises 2024 guidance slightly following Q2 results (updated)
DiaSorin slightly raises 2024 guidance following Q2 results
Brief: Diasorin Q2 Adj EBITDA At EUR 102 Mln
Italy - Factors to watch on July 29
Diasorin rises on new product clearance from U.S. FDA